<DOC>
	<DOCNO>NCT01986543</DOCNO>
	<brief_summary>We propose first interaction study efavirenz ( EFV ) R20mg/Kg take consideration absence data R induction dose . Due important inter-patient variability CYP2B6 polymorphism , EFV pharmacokinetic ( Pk ) compare patient without TB treatment . The main objective compare Pk parameter EFV HIV-TB co-infected patient , without TB treatment , use R 10 20mg/Kg/day EFV 600 800mg/day .</brief_summary>
	<brief_title>Interaction Between High Dose Rifampicine Efavirenz Pulmonary Tuberculosis HIV Co-infection</brief_title>
	<detailed_description>Justification : In vitro animal study show increase dose rifampicin ( R ) improve R sterilise effect . If similar effect demonstrate clinical setting , could allow shorten treatment duration 6 4 month , good tolerance . Several phase 2 trial HIV-negative patient ongoing . We propose first interaction study efavirenz ( EFV ) R20mg/Kg take consideration absence data R induction dose . Due important inter-patient variability CYP2B6 polymorphism , EFV pharmacokinetic ( Pk ) compare patient without TB treatment . Principal objective : To compare Pk parameter EFV HIV-TB co-infected patient , without TB treatment , use R 10 20mg/Kg/day EFV 600 800mg/day . Secondary objective : To describe Pk parameter R isoniazid ( H ) ; TB treatment réponse ( Mycobacterium tuberculosis culture conversion 8 week ( w ) cure 24w ) ; virological response ; occurrence severe adverse event , especially hepatic neurological event ; treatment adherence ; gene involve EFV metabolism EFV , R H , relation Pk parameter . Primary endpoint : AUC0-24 , Cmax , Cmin , Tmax EFV 4w TB treatment + ARV , 4w interruption TB treatment . Study design : phase 2 randomize , open label 3 arm therapeutic trial : - Arm 1 : 8 week R20mg/Kg + H + pyrazinamide ( Z ) + ethambutol ( E ) EFV600mg/J + tenofovir-lamivudine - Arm 2 : 8 week R20mg/Kg + H+Z+E EFV800mg/J + tenofovir-lamivudine - Standard arm : 8 week R10mg/Kg + H+Z+E EFV600mg/J + tenofovir-lamivudine The ARV treatment initiate 4 week start TB treatment . After 8 week , patient receive 16 week H+R R 10mg/Kg/day EFV 600mg/day . Treatment observe home domiciliary treatment monitor ( DTM ) . Patients follow 28 week start TB treatment : weekly visit first 8 week every 4 week . Pk sample EFV , R H w2 ( Pk1 ) , w8 ( Pk2 ) w28 ( Pk3 ) . Liver function test full blood count measure 2 , 4 8 week ; sputum culture TB baseline w8 ; HIV-1 RNA baseline , w4 , w12 w24 CD4 count baseline w24 . Eligibility criterion : &gt; 18 year old ; previously untreated pulmonary TB ; Xpert confirm Mtb susceptible R ; body weight &gt; 45Kg ; CD4 50 250cells/mm3 ; Karnofsky score &gt; 80 % ; ALAT/biluribin &lt; 5xULN ; grade 4 clinical/biological sign ; pregnancy + barrier contraception ; agree participate sign consent form . Randomisation block , 1:1:1 . Sample size : 28 patient show reduction AUC EFV R20mg/Kg v R great 30 % , 20 % expect reduction . Same number per study arm 20 % increase patient ' withdrawal lose follow-up result total 105 patient . Site : Mbarara ( Uganda )</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Aged 18 year Diagnosis new pulmonary tuberculosis confirm XpertMTB/RIF test Positive HIV antibody test , naïve ART CD4 cell count 50 250cells/mm3 For woman childbearing age , negative urine test pregnancy day enrolment accept take barrier contraception period trial Participants well enough receive ambulatory treatment Weight &gt; 45Kg Home address readily accessible Participants provide informed consent participate trial Rifampicin drug resistance base XpertMTB/RIF result confirm GenotypeMTBDRplus assay Concomitant opportunistic infection require additional infectious medication Karnofsky score &lt; 80 % ALAT bilirubin &gt; 5.0 x ULN ( hepatitis grade 3 4 ) Haemoglobin &lt; 7.5g/dL ( grade 3 4 ) Grade 4 clinical sign biological result accord ANRS grade intensity adverse event Patient able give inform consent unlikely unable cooperate sampling procedure Patient suffer psychiatric illness , may prevent followup accord protocol Patients receive require medication may interfere study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacokinetic</keyword>
</DOC>